Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business As Usual For Kaiser

This article was originally published in RPM Report

Executive Summary

Kaiser is a big force in pharmaceutical purchasing in the US, but the health plan is not making a big move under the Medicare Part D program.

You may also be interested in...



Playing Offense in Part D: Three Aggressive Medicare Strategies Demand Pharma Attention

Humana thrilled CMS-and shocked its competitors-by offering stand-alone drug insurance plans under Medicare for less than $10 per month. Pharmaceutical manufacturers should applaud. Not all Part D strategies are equal for pharma companies. Manufacturers should compare Humana's approach to other aggressive bids by UnitedHealth and WellCare.

Medicare Market Share: Drug Plan Starts With Big Four

Pharmaceutical manufacturers interested in maximizing their market share under the new Medicare drug benefit in 2006 should focus on four insurers likely to take the lion's share of enrollment. Dozens of plans are entering the market, but UnitedHealth Group, Wellpoint, Humana and Wellcare will start with a big edge in enrollment as of January 1. An analysis by The RPM Report explains why.

QUOTED. 28 September 2020. Kyle Sampson.

If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel